ANDA 80874, held by Impax Labs. Piperazine Citrate.
As of Nov 16, 2026, ANDA 80874 (Piperazine Citrate), held by Impax Labs, was first approved by FDA on Jul 19, 1973, with 2 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 19, 1973 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Piperazine CitrateEQ 250MG BASE ยท tablet;oral | Piperazine Citrate | Discontinued |
| May 24, 1989 | Supplement 4Labeling | Approved | None posted |
| Feb 6, 1986 | Supplement 3Manufacturing | Approved | None posted |
| Jul 19, 1973 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters